The unprecedented changes in the healthcare distribution and pharmaceutical industry have placed consumers at the forefront. This has to do with the consumer’s demands for patient-centric care delivery across geographies and socio-economic groups while fueling innovation for the industry’s products and services.
The resilience of the UAE’s healthcare distribution and pharmaceutical industry is attributed to more than its investments and global public–private partnerships. It has more to do with the relentless efforts to achieve accessibility to the industry and what it has to offer, which undeniably reflects in the national campaigns, measures, and procedures which the UAE actively took in response to the 2020 pandemic.
The constant efforts to minimise the heavy reliance on pharmaceutical imports by encouraging local production have equally contributed to placing the UAE among the MENA region’s leading pharmaceutical distributors, importers, and manufacturers. It encourages the contribution of multicultural parties to its various sectors and industries, which attracts major international pharma companies to set roots in the UAE.
The pharmaceutical industry in the UAE is expected to grow to approximately USD 3bn in 2024. In Jafza, on the other hand, the industry accounts for an average of 192 companies, with a volume of trade that points out to pharmaceutical drugs are the highest pharmaceutical product inside Jafza to import and export.